Phase II trial of thymoglobulin [antithymocyte globulin] and melphalan in patients with relapsed multiple myeloma

Trial Profile

Phase II trial of thymoglobulin [antithymocyte globulin] and melphalan in patients with relapsed multiple myeloma

Discontinued
Phase of Trial: Phase II

Latest Information Update: 14 Feb 2017

At a glance

  • Drugs Antithymocyte globulin (Primary) ; Melphalan (Primary)
  • Indications Multiple myeloma
  • Focus Therapeutic Use
  • Most Recent Events

    • 01 Oct 2010 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
    • 02 Jul 2010 Actual end date (Jan 2010) added as reported by ClinicalTrials.gov.
    • 02 Jul 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top